

ARADIGM CORP
Form 8-K
August 12, 2003

Table of Contents

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **August 6, 2003**

ARADIGM CORPORATION

(Exact name of registrant as specified in its charter)

California

(State or other jurisdiction of incorporation)

0-28402

(Commission File No.)

94-3133088

(IRS Employer Identification No.)

**3929 Point Eden Way
Hayward, California 94545**

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(510) 265-9000**

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

TABLE OF CONTENTS

Item 7. Exhibits.

Item 9. Regulation FD Disclosure

SIGNATURES

INDEX TO EXHIBITS

EXHIBIT 99.1

Table of Contents

INFORMATION TO BE INCLUDED IN THE REPORT

Item 7. Exhibits.

Exhibit Number	Description
99.1	Transcript of call held on August 6, 2003.

Item 9. Regulation FD Disclosure

On August 6, 2003, Aradigm Corporation (the Company) held a conference call to discuss the status of ongoing and future clinical trials and commercial scale-up preparations with regard to the Company's AERx insulin Diabetes Management System. A transcript of the call is being furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ARADIGM CORPORATION

Dated: August 11, 2003

By: /S/ THOMAS C. CHESTERMAN

Thomas C. Chesterman

Title: Senior Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)

Table of Contents

INDEX TO EXHIBITS

Exhibit Number	Description
99.1	Transcript of call held on August 6, 2003.